Among the mAbs that bind to the extracellular domain of c-MET, the fully humanized monovalent mAb onartuzumab (MetMAb, Genentech, South San Francisco, California, USA) has been evaluated in several clinical trials, but failed to show improvement when given in combination with erlotinib in patients with MET -positive NSCLC [21, 22, 99]
Ozempic Prescribed for Weight Loss (Off-Label): Confirm payer coverage for weight loss before prescribing Ozempic for obesity alone
Participants in the trial had an average age of 44.7 years, a mean body weight of 113 kg (249 lbs), and a body mass index (BMI) of 39.4 kg/m
In 2025, the European Medicines Agency recommended updating semaglutide product information to include NAION as a very rare side effect
2018;50:e12927
on this page Obesity is a chronic disease that results from an imbalance of endogenous and environmental exposures, such as basal metabolic rate, energy expenditure, and food intake